In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations
Open accessAbstract
Ibrexafungerp is a first-in-class glucan synthase inhibitor. In vitro activity was determined for 89 Candida glabrata isolates with molecularly identified FKS1 or FKS2 mutations conferring resistance to the echinocandins. All isolates were resistant to at least one echinocandin (i.e., anidulafungin, caspofungin, or micafungin) by broth microdilution. Results for ibrexafungerp were compared with those for each echinocandin.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
IBX has strong activity across a broad range of fungi.
“IBX introduces a novel mechanism, potent broad spectrum of activity and a safe oral formulation”
From Investigational Agents for the Treatment of Resistant Yeasts and Molds (2021) · cites this paper as [24]
Cites
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · see citing works
Lockhart, S. R., Iqbal, N., Cleveland, A. A., Farley, M. M., Harrison, L. H., Bolden, C. B., Baughman, W., Stein, B., Hollick, R., Park, B. J., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01283-12 · Cited by 299 · see citing works
Self-citationPham, C. D., Iqbal, N., Bolden, C. B., Kuykendall, R. J., Harrison, L. H., Farley, M. M., Schaffner, W., Beldavs, Z. G., Chiller, T. M., Park, B. J., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03255-14 · Cited by 231 · see citing works
Self-citationEspinel-Ingroff, A., Arendrup, M. C., Pfaller, M. A., Bonfietti, L. X., Bustamante, B., Canton, E., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, E., Fothergill, A., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01519-13 · Cited by 216 · see citing works
Self-citationJiménez‐Ortigosa, C., Paderu, P., Motyl, M. R., & Perlin, D. S. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02145-13 · Cited by 122 · see citing works
Berkow, E. L., Angulo, D. A., & Lockhart, S. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00435-17 · Cited by 103 · see citing works
Self-citationLepak, A. J., Marchillo, K., & Andes, D. R. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04445-14 · Cited by 95 · see citing works
Jiménez-Ortigosa, C., Perez, W. B., Angulo, D., Borroto-Esoda, K., & Perlin, D. S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00833-17 · Cited by 89 · see citing works
Self-citationPfaller, M. A., Messer, S. A., Rhomberg, P. R., Borroto-Esoda, K., & Castanheira, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00161-17 · Cited by 84 · see citing works
Larkin, E. L., Long, L., Isham, N. C., Borroto–Esoda, K., Barat, S., Angulo, D., Wring, S., & Ghannoum, M. A. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02611-18 · Cited by 52 · see citing works
Self-citationCandidemia surveillance in Iowa: emergence of echinocandin resistance
Matsumoto, E., Boyken, L., Tendolkar, S., McDanel, J., Castanheira, M., Pfaller, M., & Diekema, D. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.02.016 · Cited by 50 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467 · see citing works
Aspiring Antifungals: Review of Current Antifungal Pipeline Developments
Gintjee, T., Donnelley, M., & Thompson, G. (2020) · Journal of Fungi · doi:10.3390/jof6010028 · Cited by 225 · see citing works
Hoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 160 · see citing works
Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
Jallow, S., & Govender, N. P. (2021) · Journal of Fungi · doi:10.3390/jof7030163 · Cited by 129 · see citing works
Review on Current Status of Echinocandins Use
Mroczyńska, M., & Brillowska‐Dąbrowska, A. (2020) · Antibiotics · doi:10.3390/antibiotics9050227 · Cited by 108 · see citing works
Giannella, M., Lanternier, F., Dellière, S., Groll, A. H., Mueller, N. J., Alastruey‐Izquierdo, A., & Slavin, M. A. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.08.006 · Cited by 95 · see citing works
Ghannoum, M. A., Arendrup, M. C., Chaturvedi, V. P., Lockhart, S. R., McCormick, T. S., Chaturvedi, S., Berkow, E. L., Juneja, D., Tarai, B., Azie, N. E., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9090539 · Cited by 92 · see citing works
Self-citationAntifungal Resistance and the Role of New Therapeutic Agents
Logan, A., Wolfe, A. L., & Williamson, J. (2022) · Current Infectious Disease Reports · doi:10.1007/s11908-022-00782-5 · Cited by 87 · see citing works
Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis
Murphy, S. E., & Bicanic, T. A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.759408 · Cited by 85 · see citing works
Novel antifungal agents in clinical trials
Jacobs, S. E., Zagaliotis, P., & Walsh, T. J. (2021) · F1000Research · doi:10.12688/f1000research.28327.1 · Cited by 75 · see citing works
Wiederhold, N. P. (2022) · Journal of Fungi · doi:10.3390/jof8080857 · Cited by 68 · see citing works
Lee, A. (2021) · Drugs · doi:10.1007/s40265-021-01571-5 · Cited by 59 · see citing works
Gamal, A., Chu, S., McCormick, T. S., Borroto-Esoda, K., Angulo, D., & Ghannoum, M. A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.642358 · Cited by 58 · see citing works
Self-citationKeshri, P. K., Rai, N., Verma, A. K., Kamble, S. C., Barik, S., Mishra, P., Singh, S. K., Salvi, P., & Gautam, V. (2021) · Mycological Progress · doi:10.1007/s11557-021-01695-8 · Cited by 58 · see citing works
Amphotericin B in the Era of New Antifungals: Where Will It Stand?
Akinosoglou, K., Rigopoulos, E. A., Papageorgiou, D., Schinas, G., Polyzou, E., Dimopoulou, E., Gogos, C. A., & Dimοpoulos, G. (2024) · Journal of Fungi · doi:10.3390/jof10040278 · Cited by 56 · see citing works
McCarty, T. P., & Pappas, P. G. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.732223 · Cited by 47 · see citing works
Oral Ibrexafungerp: An Investigational Agent for the Treatment of Vulvovaginal Candidiasis
Azie, N., Angulo, D., Dehn, B., & Sobel, J. D. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1791820 · Cited by 46 · see citing works
Self-citationHoenigl, M., Sprute, R., Arastehfar, A. A., Perfect, J. R., Lass‐Flörl, C., Bellmann, R., Prattes, J., Thompson, G. R., Wiederhold, N. P., Al‐Obaidi, M. M., et al. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2086120 · Cited by 46 · see citing works
Arastehfar, A. A., Daneshnia, F., Salehi, M., Yaşar, M., Hoşbul, T., İlkit, M., Pan, W., Hagen, F., Arslan, N. P., Dağı, H. T., et al. (2020) · Mycoses · doi:10.1111/myc.13104 · Cited by 42 · see citing works
Quindós, G., Miranda-Cadena, K., San-Millán, R., Borroto–Esoda, K., Cantón, E., Linares-Sicilia, M. J., Hamprecht, A. G., Montesinos, I., Tortorano, A. M., Prigitano, A., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.906563 · Cited by 41 · see citing works
Self-citationHow urgent is the need for new antifungals?
Stewart, A. G., & Paterson, D. L. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1935868 · Cited by 36 · see citing works
Investigational Agents for the Treatment of Resistant Yeasts and Molds
Seiler, G. T., & Ostrosky-Zeichner, L. (2021) · Current Fungal Infection Reports · doi:10.1007/s12281-021-00419-5 · Cited by 32 · see citing works
New antifungal strategies and drug development against WHO critical priority fungal pathogens
Li, Y., Liu, Y., Jiang, Y., Yang, Y., Ni, W., Zhang, W., & Tan, L. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1662442 · Cited by 36 · see citing works
The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives
de Souza, C. M., Bezerra, B. T., Mellon, D. A., & de Oliveira, H. C. (2025) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2025.100341 · Cited by 35 · see citing works
Mesquida, A., Díaz-García, J., Sánchez‐Carrillo, C., Muñóz, P., Escribano, P., & Guinea, J. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.030 · Cited by 30 · see citing works
Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
McCarthy, M. W. (2022) · Drugs in R&D · doi:10.1007/s40268-021-00376-x · Cited by 28 · see citing works
Ibrexafungerp: A narrative overview
Ayoubi, L. W. E., Allaw, F., Moussa, E., & Kanj, S. S. (2024) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2024.100245 · Cited by 27 · see citing works
Emerging Diagnostics and Therapeutics for Invasive Fungal Infections
Friedman, D. Z. P., & Schwartz, I. S. (2023) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2023.05.001 · Cited by 23 · see citing works
The Significance of Mono‐ and Dual‐Effective Agents in the Development of New Antifungal Strategies
Zobi, C., & Algül, Ö. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70045 · Cited by 22 · see citing works
Ibrexafungerp: A new triterpenoid antifungal
Sucher, A. J., Thai, A., Tran, C., Mantena, N., Noronha, A., & Chahine, E. B. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac256 · Cited by 21 · see citing works
Treatment of invasive candidiasis in the era of Candida resistance
Paiva, J.-A., & Pereira, J. M. (2023) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001077 · Cited by 24 · see citing works
Aldejohann, A. M., Menner, C., Thielemann, N., Martin, R., Walther, G., & Kurzai, O. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01324-23 · Cited by 20 · see citing works
Mesquida, A., Díaz-García, J., Sánchez‐Carrillo, C., Martín‐Rabadán, P., Alcalá, L., Muñóz, P., Escribano, P., & Guinea, J. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.04.003 · Cited by 19 · see citing works
Quiles‐Melero, I., & García‐Rodríguez, J. (2021) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2021.04.004 · Cited by 18 · see citing works
de Sousa, I. P., Ferreira, A. G., Crotti, A. E. M., dos Santos, R. A., Kiermaier, J., Kraus, B., Heilmann, J., & Furtado, N. A. J. C. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103560 · Cited by 16 · see citing works
Vicente, F., Reyes, F., & Genilloud, O. (2024) · Natural Product Reports · doi:10.1039/d4np00044g · Cited by 14 · see citing works
Resilience in Resistance: The Role of Cell Wall Integrity in Multidrug-Resistant Candida
Banda-Flores, I. A., Torres‐Tirado, D., Mora-Montes, H. M., Pérez‐Flores, G., & Pérez-García, L. A. (2025) · Journal of Fungi · doi:10.3390/jof11040271 · Cited by 15 · see citing works
An evaluation of ibrexafungerp for the treatment of invasive candidiasis: the evidence to date
Colombo, R. E., & Vázquez, J. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1890026 · Cited by 14 · see citing works
Jain, K., Wadhwa, K., MALIK, M. L., Haque, S., Prieto, M. A., & Kaur, H. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf742 · Cited by 11 · see citing works
Fungal β-1,3-glucan synthase: a review of structure, mechanism, and regulation
Huang, X.-T., Chen, M., Chen, Z., & Zhang, Y.-P. (2025) · FEMS Yeast Research · doi:10.1093/femsyr/foaf071 · Cited by 11 · see citing works
EUCAST Ibrexafungerp MICs and Wild-Type Upper Limits for Contemporary Danish Yeast Isolates
Jørgensen, K. M., Astvad, K. M. T., Hare, R. K., & Arendrup, M. C. (2022) · Journal of Fungi · doi:10.3390/jof8101106 · Cited by 10 · see citing works
Inhibition mechanism of the fungal β−1,3-glucan synthases by triterpenoid antifungal drugs
You, Z.-L., Sun, L., Wang, L.-X., Ni, Y.-R., Lyu, R., Chen, D., Yun, C.-H., Song, T., Song, Y., & Bai, L. (2026) · Nature Communications · doi:10.1038/s41467-026-69114-8 · Cited by 8 · see citing works
Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix
August, B., & Kale-Pradhan, P. B. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2926 · Cited by 8 · see citing works
Tan, X., Baugh, K., Bulman, Z. P., & Wenzler, E. (2020) · Current Fungal Infection Reports · doi:10.1007/s12281-020-00388-1 · Cited by 6 · see citing works
TO MARKET, TO MARKET–2021: SMALL MOLECULES
Araujo, E., Bell, I. M., Burckle, A. J., Koester, D. C., Manning, J. R., Caldwell, R. D., Castanedo, G. M., Green, S. A., Zeng, M., Debien, L., et al. (2022) · Medicinal chemistry reviews · doi:10.1021/mc-2022-vol57.ch24 · Cited by 6 · see citing works
A review of the fernane-type triterpenoids as anti-fungal drugs
Liu, C., Zhang, L., Liu, S.-X., Lu, Y., Li, C., & Pei, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1447450 · Cited by 5 · see citing works
Ma, J., Eadie, K., Konings, M., Fahal, A. H., Verbon, A., & van de Sande, W. W. J. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf133 · Cited by 5 · see citing works
Therapeutic Tools for Vulvovaginal Candidiasis: Current and Emerging Antifungal Agents
Quindós, G., De-la-Pinta, I., Marcos‐Arias, C., Jauregizar, N., Sevillano, E., Madariaga, L., & Eraso, E. (2026) · Journal of Fungi · doi:10.3390/jof12020152 · Cited by 4 · see citing works
Rhodes, J. L. (2025) · Current topics in microbiology and immunology · doi:10.1007/82_2025_327 · Cited by 3 · see citing works
Thaweboon, S., Kedcharoen, P., Wongsirichat, N., & Thaweboon, B. (2020) · Key engineering materials · doi:10.4028/www.scientific.net/kem.862.130 · Cited by 3 · see citing works
New Antifungal Drugs: Discovery and Therapeutic Potential
Vicente, F., Reyes, F., & Genilloud, O. (2024) · Springer eBooks · doi:10.1007/978-981-99-5696-8_12 · Cited by 3 · see citing works
The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis
Zubovskaia, A., & Vázquez, J. A. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s547511 · Cited by 2 · see citing works
Candida glabrata Prosthetic Joint Infection Managed with Ibrexafungerp
Nadarevic, E., McHugh, J., & Vergidis, P. I. (2025) · Journal of Fungi · doi:10.3390/jof11060442 · Cited by 2 · see citing works
Holt, C. J. D., Williams, C. C., & Usher, J. (2026) · Journal of Medical Microbiology · doi:10.1099/jmm.0.002127 · Cited by 1 · see citing works
Morelo, M. J., Firacative, C., García‐Effrón, G., Gómez, B. L., & Ceballos-Garzón, A. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107870 · Cited by 1 · see citing works
Finkina, E. I., Shevchenko, O. V., Gerasimova, А. А., Fateeva, S. I., Баландин, С. В., & Ovchinnikova, T. V. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188141 · Cited by 1 · see citing works
Novel Antifungals for the Treatment of Vulvovaginal Candidiasis: Where Are We?
Gamal, A., authorship, T. A. H. C. E. T. T. W. A. S. F., Kadry, A., authorship, T. A. H. C. E. T. T. W. A. S. F., Elshaer, M. Y. S., & Ghannoum, M. A. (2022) · touchREVIEWS in Infectious Diseases · doi:10.17925/id.2022.1.1.16 · Cited by 1 · see citing works
Promising antimycotics for the treatment of invasive infections
Ortenberg, E. A. (2023) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2023.2.165-170 · Cited by 1 · see citing works
Hope in the Treatment of Candida Vaginitis: Ibrexafungerp
Karakoyun, A. S. (2021) · Türk Mikrobiyoloji Cemiyeti Dergisi · doi:10.5222/tmcd.2021.71602 · Cited by 1 · see citing works
Yang, P., Qi, C., Du, S., Hu, X., Hua, Z., Yang, Y., Zhang, D., Ke, Y., Zhang, M., Liu, X., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.07.704550 · Cited by 1 · see citing works
Brown, L. K., Stone, N. R. H., & Coughlan, C. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00165-1
Lockhart, S. R., & Berkow, E. L. (2023) · ClinMicroNow · doi:10.1002/9781683674849.mcm0133
Self-citationLockhart, S. R., & Berkow, E. L. (2023) · ClinMicroNow · doi:10.1002/9781683670438.mcm0133
Self-citationAl‐Obaidi, M. M., Nematollahi, S., Hayes, J. F., & Nix, D. E. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2651278
Emerging antifungal agents in human medicine: Mechanisms, clinical progress, and future perspectives
Al‐Zoubi, R. M., Farhan, A., Hanbali, B., Al-Zoubi, S. R., Al-Zoubi, Y. R., Shkoor, M., Alkharraz, L. M., Agouni, A., & Al-Jabiry, A. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119194
Lather, P., Tilak, R., Mahor, A., Khuraijam, R., Bagga, R., Saha, P. K., Rudramurthy, S. M., Reddy, S., Verma, S., Kumari, S., et al. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-05234-5
- Authors
- Nunnally, N. S., Etienne, K. A., Angulo, D., Lockhart, S. R., & Berkow, E. L.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Scynexis (United States) (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2019-11
- Volume
- 63
- Issue
- 11
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC6811432
- OpenAlex
- W2971516890
- Cited by
- 66
- References
- 11
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 9 · 2023: 5 · 2022: 9 · 2021: 16 · 2020: 7 · 2019: 1
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- ibrexafungerp, Candida glabrata, echinocandin resistance, FKS1 mutations, anidulafungin, caspofungin, micafungin, antifungal susceptibility, in vitro antifungal activity
- MeSH terms
- Antifungal Agents, Genes, Fungal, Glucosyltransferases, Glycosides, Microbial Sensitivity Tests, Mutation, Triterpenes, Drug Resistance, Fungal, Candida glabrata, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
